Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CDLX vs EHTH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EHTH Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–4 Matrix Metrics)

EHTH Overall Winner 6-Pillar Tally: CDLX 2 – 4 EHTH Matrix Metrics: CDLX 4 – 5 EHTH

As of Nov 17, 2026, eHealth, Inc. (EHTH) is the stronger overall head-to-head candidate over Cardlytics, Inc. (CDLX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CDLX carries a Unified Composite Score of 41.6/100 (SELL) at $1.29 (36.5x Forward P/E, -19.3% operating margin), whereas EHTH carries 40.8/100 (SELL) at $0.35 (0.2x Forward P/E, 11.9% operating margin).

  • Composite vs. Pillar Nuance: While CDLX currently prints a higher short-term Unified Composite Score (41.6/100 SELL vs. EHTH 40.8/100 SELL), EHTH captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (11.9% vs. -19.3% operating margin) and revenue trajectory (-60.5% vs. -30.0% YoY).
  • Defensive Composite Rating Caution: Although EHTH compares more favorably head-to-head, both CDLX (41.6/100 SELL) and EHTH (40.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: CDLX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.8); meanwhile EHTH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CDLX vs EHTH
CDLX NASDAQ
Cardlytics, Inc. Common Stock
Services-Computer Programming, Data Processing, Etc.
$1.29
+0.0% 1D
Market Cap $8.2M
TTM Revenue $176M
Forward P/E 36.5x
Beta / 30D Vol 1.76β · 107% Vol
Unified Composite Score
41.6 / 100 SELL
Tech 25.0 Fund 46.0 Flow 60.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -27.0%), weak momentum, RSI 26
RSI-14: 25.8 · SMA20: $1.73 · SMA50: $2.49
EHTH NASDAQ Head-to-Head Winner
eHealth, Inc.
Insurance Agents, Brokers & Service
$0.35
-8.6% 1D
Market Cap $13.4M
TTM Revenue $469M
Forward P/E 0.2x
Beta / 30D Vol 1.58β · 112% Vol
Unified Composite Score
40.8 / 100 SELL
Tech 25.0 Fund 44.0 Flow 50.0 Mom 63.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.4%), weak momentum, RSI 25
RSI-14: 24.9 · SMA20: $0.50 · SMA50: $0.65

6-Pillar Scorecard Institutional Category Breakdown (CDLX 2 – 4 EHTH)

Columns: Metric · CDLX · EHTH
1. Valuation Multiples EHTH
Forward P/E 36.5x 0.2x
Trailing P/E 36.5x 0.2x
PEG Ratio N/M 0.72x
EV / Revenue N/M N/M
2. Growth & Scale EHTH
Revenue Growth (YoY) -30.0% -60.5%
Earnings Growth (YoY) -56.7% -17.6%
TTM Revenue (USD) $176M $469M
Market Cap $8.2M $13.4M
3. Profitability & Quality EHTH
Gross Margin 49.7% 100.0%
Operating Margin -19.3% 11.9%
Net Profit Margin -20.8% 4.9%
Return on Equity (ROE) -513.2% 2.6%
4. Balance Sheet & Cash Flow EHTH
Cash Generation (TTM) -$16M $58M EBITDA
Cash Flow Margin -9.2% 12.4% EBITDA Mgn
Net Cash / Leverage -513.2% ROE $15.36 Book/Sh · 2.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CDLX
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 0.8% (<1st %ile) 128.7% (56th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat CDLX
OpEx & R&D Intensity 69.0% of Rev ($121M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Advertising Agencies Operator Insurance Brokers Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CDLX (4) vs EHTH (5)
Institutional Metric CDLX EHTH Criterion Row Edge
Market Capitalization
Scale
$8.2M $13.4M Larger Scale Tie
Trailing P/E Ratio
Valuation
36.5x 0.2x Lower Multiple EHTH
Forward P/E Ratio
Valuation
36.5x 0.2x Lower Multiple EHTH
Revenue Growth (YoY)
Growth
-30.0% -60.5% Higher Growth CDLX
Operating Margin (TTM)
Profitability
-19.3% 11.9% Higher Margin EHTH
Net Profit Margin
Profitability
-20.8% 4.9% Higher Margin EHTH
Return on Equity (ROE)
Capital Efficiency
-513.2% 2.6% Higher ROE EHTH
52-Week Range Position
Momentum
13% ($1–$6) 1% ($0–$5) Stronger Trend CDLX
Beta / 30D Volatility
Risk Regime
1.76β · 107% Vol 1.58β · 112% Vol Lower Realized Risk CDLX
Unified Institutional Score
Composite Signal
41.6 / 100 (SELL) 40.8 / 100 (SELL) Higher Composite CDLX
Trailing 12M Revenue (USD)
Operating Scale
$176M $469M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
49.7% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.72x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$16M (-513.2% ROE) $58M EBITDA ($15.36 Book/Sh · 2.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDLX +8.23 pp
CDLX: -29.89% · EHTH: -38.12%
3M Horizon CDLX +2.08 pp
CDLX: -69.72% · EHTH: -71.8%
6M Horizon CDLX +196.57 pp
CDLX: +116.44% · EHTH: -80.13%
1Y Horizon CDLX +83.66 pp
CDLX: -7.19% · EHTH: -90.85%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CDLX vs EHTH. Trailing 12-month operating profitability (CDLX -19.3% vs EHTH 11.9%) and valuation multiples (CDLX 36.5x vs EHTH 0.2x Forward P/E) are benchmarked directly in Pillar 4 below.

CDLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$176M
Gross Margin49.7%
Op. Margin-19.3%
ROE / Fwd P/E-513.2% · 36.5x
EHTH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$469M
Gross Margin100.0%
Op. Margin11.9%
ROE / Fwd P/E2.6% · 0.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CDLX BREAKDOWN
109d in phase · OBV NEUTRAL
Current IV 0.8%
IV Percentile <1st %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EHTH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 128.7%
IV Percentile 56th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EHTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CDLX Moat Profile Cyclical / Execution-Driven Positioning
Advertising Agencies Operator
Competes within the Advertising Agencies value chain with $8.2M market capitalization and -19.3% operating margin.
OpEx & R&D Reinvestment 69.0% of Rev ($121M)
90D Engineering Disclosures 0 Published
EHTH Moat Profile Cyclical / Execution-Driven Positioning
Insurance Brokers Operator
Competes within the Insurance Brokers value chain with $13.4M market capitalization and 11.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CDLX vs EHTH Key Questions & Quantitative Answers

As of Nov 17, 2026, eHealth, Inc. (EHTH) is the stronger overall head-to-head candidate over Cardlytics, Inc. (CDLX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CDLX carries a Unified Composite Score of 41.6/100 (SELL) at $1.29 (36.5x Forward P/E, -19.3% operating margin), whereas EHTH carries 40.8/100 (SELL) at $0.35 (0.2x Forward P/E, 11.9% operating margin). Composite vs. Pillar Nuance: While CDLX currently prints a higher short-term Unified Composite Score (41.6/100 SELL vs. EHTH 40.8/100 SELL), EHTH captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (11.9% vs. -19.3% operating margin) and revenue trajectory (-60.5% vs. -30.0% YoY). Defensive Composite Rating Caution: Although EHTH compares more favorably head-to-head, both CDLX (41.6/100 SELL) and EHTH (40.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: CDLX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.8); meanwhile EHTH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EHTH leads the Growth & Scale pillar: CDLX posts -30.0% YoY revenue growth and -56.7% YoY earnings growth on $176M TTM revenue (49.7% gross margin, -19.3% operating margin), compared with EHTH at -60.5% YoY revenue growth and -17.6% YoY earnings growth on $469M TTM revenue (100.0% gross margin, 11.9% operating margin). On trailing 12-month operating scale, CDLX generates $176M in USD-normalized revenue versus $469M for EHTH. In operating R&D and SG&A reinvestment, CDLX deploys 69.0% of Rev ($121M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EHTH.

EHTH screens cheaper on headline valuation multiples. CDLX trades at 36.5x Forward P/E, 36.5x Trailing P/E, N/M PEG, and N/M EV/Revenue (-9.2% FCF margin), whereas EHTH trades at 0.2x Forward P/E, 0.2x Trailing P/E, 0.72x PEG, and N/M EV/Revenue (12.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CDLX (-513.2% ROE) versus EHTH (2.6% ROE) capital efficiency.

In options market volatility and institutional positioning, CDLX carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.76β · 107% Vol realized risk). By comparison, EHTH carries 128.7% implied volatility (56th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.58β · 112% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.